Who Owns Sagimet Biosciences Series A Stock?
NASDAQ: SGMTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 77.14%
- Held by insiders
- 2.95%
- Institutional holders
- 171
- Institutions 77.1%
- Insiders 3.0%
- Public and other 19.9%
Who owns Sagimet Biosciences Series A stock?
Institutional investors own about 77.1% of Sagimet Biosciences Series A's shares, spread across 171 institutions that file 13F reports. That level of institutional ownership is high, typical of large, widely followed companies. Insiders, including executives, directors and large founding shareholders, hold 2.95% of SGMT.
The largest institutional holders are Blackrock Inc. (10.68%), Balyasny Asset Management LP (5.89%) and Woodline Partners LP (4.87%). Together, the top 10 institutions control 49.2% of shares outstanding. In their latest filings, 10 of the top 10 institutions increased their SGMT positions and 0 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of SGMT
| Institution | Shares | % Held | Change |
|---|---|---|---|
| Blackrock Inc. | 6.58M | 10.68% | +722.0% |
| Balyasny Asset Management LP | 3.63M | 5.89% | +100.0% |
| Woodline Partners LP | 3.00M | 4.87% | +199.8% |
| SilverArc Capital Management, LLC | 2.93M | 4.75% | +100.0% |
| Vanguard Capital Management LLC | 2.57M | 4.17% | +133.5% |
| BVF Inc. | 2.50M | 4.06% | +100.0% |
| Caligan Partners, LP | 2.50M | 4.06% | +100.0% |
| Affinity Asset Advisors, Llc | 2.50M | 4.06% | +187.8% |
| Federated Hermes, Inc. | 2.09M | 3.39% | +267085.0% |
| Great Point Partners LLC | 2.03M | 3.30% | +100.0% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of SGMT
| Fund | Shares | % Held |
|---|---|---|
| Federated Hermes Equity Funds-Federated Hermes Kaufmann Small Cap Fund | 2.08M | 3.38% |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.86M | 3.02% |
| iShares Trust-iShares Russell 2000 ETF | 1.48M | 2.39% |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.04M | 1.68% |
| abrdn Life Sciences Investors | 847.70K | 1.38% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 659.00K | 1.07% |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 643.41K | 1.04% |
| BlackRock Funds-BlackRock Health Sciences Opportunities Portfolio | 585.18K | 0.95% |
| iShares Trust-iShares Biotechnology ETF | 436.66K | 0.71% |
| iShares Trust-iShares Russell 2000 Growth ETF | 434.82K | 0.71% |
Frequently asked questions
Who is the largest shareholder of Sagimet Biosciences Series A?
Blackrock Inc. is the largest institutional shareholder of SGMT, owning 10.68% of shares outstanding (6.58M shares) as of its latest 13F filing.
What percentage of Sagimet Biosciences Series A is owned by institutions?
Institutions own about 77.1% of SGMT shares and 79.5% of the public float.
How much of Sagimet Biosciences Series A do insiders own?
Insiders, such as officers and directors, own about 2.95% of SGMT shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.